NASDAQ:KLDO

Kaleido Biosciences - KLDO Stock Forecast, Price & News

$0.0002

0.00 (0.00%)

(As of 03/31/2023 09:30 AM ET)

Add

Compare

Today's Range: $0.0002
▼
$0.0002
50-Day Range: N/A
52-Week Range: $0.00
▼
$0.14

Volume: 156 shs
Average Volume: 12,712 shs
Market Capitalization: $8,524.60

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.70

Institutional Ownership

Kaleido Biosciences MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 849,900.0% Upside
$1.70 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.13
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.27) to ($1.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Kaleido Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.70, Kaleido Biosciences has a forecasted upside of 849,900.0% from its current price of $0.00.
Amount of Analyst Coverage
Kaleido Biosciences has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for KLDO.

0.0

Dividend Strength

Dividend Yield
Kaleido Biosciences does not currently pay a dividend.
Dividend Growth
Kaleido Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KLDO.

1.7

News and Social Media Coverage

News Sentiment
Kaleido Biosciences has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Kaleido Biosciences this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Kaleido Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kaleido Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Kaleido Biosciences is held by insiders.
Percentage Held by Institutions
81.56% of the stock of Kaleido Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Kaleido Biosciences are expected to grow in the coming year, from ($2.27) to ($1.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kaleido Biosciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kaleido Biosciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Kaleido Biosciences (NASDAQ:KLDO) Stock

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

March 28, 2023 | marketwatch.com

Consumer & IoT Mobile Roaming Data Traffic Expected to Triple 2019 Volume, Approaching 3,000 Petabytes in 2023: Kaleido Intelligence

December 17, 2022 | seekingalpha.com

KLDO Kaleido Biosciences, Inc.

March 31, 2023 | WealthPop (Ad)

Adam Mesh: “This Strategy Saved My Trading Career”

Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done.

November 10, 2022 | technews.tmcnet.com

VoLTE Roaming Readiness Ranked As High Priority For Mobile Operators: Kaleido Q3 2022 Mno Survey

September 27, 2022 | tmcnet.com

Syniverse Earns Industry Honors in Roaming and Data & Financial Clearing from Kaleido Intelligence

September 12, 2022 | benzinga.com

Airlinq, Tata Communications and Giesecke+Devrient, Recognised as Champion Cellular IoT Connectivity Vendors by Kaleido Intelligence

September 5, 2022 | benzinga.com

Exclusive Free Roaming Insights Available as Kaleido Becomes GSMA Member

July 26, 2022 | apnews.com

BCE To Provide $5 Billion Operator Revenue Opportunity From Permanently Roaming IoT Devices Over the Next 5 Years: Kaleido Intelligence

March 31, 2023 | Weiss Ratings (Ad)

Banking Nightmare

During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …

July 21, 2022 | msn.com

Ethereum’s Kaleido Collaborates With Polygon for Web3 Adoption

June 14, 2022 | morningstar.com

Kaleido Biosciences Inc - Stock Price vs Fair Value KLDO

June 7, 2022 | tmcnet.com

Security and Design are the biggest knots to untangle, according to the largest-ever IoT connectivity survey run by Kaleido Intelligence

May 16, 2022 | uk.finance.yahoo.com

Kaleido Biosciences, Inc. (KLDO)

April 15, 2022 | seekingalpha.com

ATER, HNRG and AGLE among mid-day movers

April 8, 2022 | benzinga.com

Kaleido Biosciences Shares Halted On Code News Pending

April 8, 2022 | finance.yahoo.com

Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why

April 8, 2022 | msn.com

Flagship’s Kaleido Biosciences shuts down, as more biotechs lay off staff

April 8, 2022 | seekingalpha.com

Kaleido Biosciences to delist from Nasdaq as business operations end

April 8, 2022 | bizjournals.com

Kaleido Biosciences shuts down

April 1, 2022 | finance.yahoo.com

Novartis (NVS) Beovu Gets Label Expansion for DME in EU

March 31, 2022 | finance.yahoo.com

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

March 25, 2022 | finance.yahoo.com

Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?

March 24, 2022 | finance.yahoo.com

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

March 16, 2022 | finance.yahoo.com

Radius Health Announces Leadership Appointments

March 15, 2022 | finance.yahoo.com

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal

March 1, 2022 | finance.yahoo.com

Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates

February 24, 2022 | finance.yahoo.com

Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Company Calendar

Last Earnings: 11/01/2021
Today: 3/31/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KLDO
CUSIP: N/A
CIK: 1751299
Web: www.kaleido.com
Phone: (617) 674-9000
Fax: N/A
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $1.70
High Stock Price Forecast: $1.70
Low Stock Price Forecast: $1.70
Forecasted Upside/Downside: +849,900.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $1.10 million
Price / Sales: 0.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 42,623,000
Free Float: 38,787,000
Market Cap: $8,524.60
Optionable: Not Optionable
Beta: -0.06

Key Executives

Kimberly Hocknell
Senior Vice President-Technical Operations

Key Competitors

View All Competitors

KLDO Stock - Frequently Asked Questions

Should I buy or sell Kaleido Biosciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KLDO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KLDO, but not buy additional shares or sell existing shares.
View KLDO analyst ratings or view top-rated stocks.
What is Kaleido Biosciences' stock price forecast for 2023?: 1 analysts have issued twelve-month price targets for Kaleido Biosciences' stock. Their KLDO share price forecasts range from $1.70 to $1.70. On average, they anticipate the company's share price to reach $1.70 in the next twelve months. This suggests a possible upside of 849,900.0% from the stock's current price.
View analysts price targets for KLDO or view top-rated stocks among Wall Street analysts.
How have KLDO shares performed in 2023?: Kaleido Biosciences' stock was trading at $0.0005 on January 1st, 2023. Since then, KLDO shares have decreased by 60.0% and is now trading at $0.0002.
View the best growth stocks for 2023 here.
How were Kaleido Biosciences' earnings last quarter?: Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.54). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.25 million.
What other stocks do shareholders of Kaleido Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?: (KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is Kaleido Biosciences' stock symbol?: Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."
How do I buy shares of Kaleido Biosciences?: Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kaleido Biosciences' stock price today?: One share of KLDO stock can currently be purchased for approximately $0.00.
How much money does Kaleido Biosciences make?: Kaleido Biosciences (NASDAQ:KLDO) has a market capitalization of $8,524.60 and generates $1.10 million in revenue each year.
How can I contact Kaleido Biosciences?: The official website for the company is www.kaleido.com. The company can be reached via phone at (617) 674-9000.

This page (NASDAQ:KLDO) was last updated on 3/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kaleido Biosciences - KLDO Stock Forecast, Price & News

Kaleido Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kaleido Biosciences (NASDAQ:KLDO) Stock

KLDO Stock News Headlines

KLDO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

KLDO Stock - Frequently Asked Questions

Overall MarketRank^™